Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Key considerations before the dust settles on a mega merger

This article was originally published in Scrip

Executive Summary

With companies carving off certain assets in their portfolios, both sellers and buyers are faced with the challenge of how to divest if they're selling, or integrate if they're buying that particular asset. With the ink only just dry on the deal, how well the company divests or integrates an asset can often make or break the success of the transaction, a factor the pharma sector understands more than most.

Advertisement
Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024667

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel